AbCellera Biologics Inc.（ABCL）股票分析ABCLAbCellera Biologics Inc.

AbCellera Biologics Inc. discovers and develops antibody medicines for indications across therapeutic areas, including cancer, metabolic and endocrine conditions, and autoimmune disorders. Its platform integrates technology, data science, infrastructure, and interdisciplinary teams to solve the challenging antibody discovery problems. It is focused on advancing an internal pipeline of programs and collaborating on drug development programs with partners. Its first two internal programs, ABCL635 and ABCL575, are in late-preclinical studies. ABCL635 is an antibody drug candidate for metabolic and endocrine conditions, and ABCL575 is an antibody drug candidate with broad potential in inflammatory conditions and autoimmune diseases and an initial indication in atopic dermatitis. ABCL575 binds OX40L to disrupt OX40/OX40L signaling, a regulator of inflammatory pathways in AD. In addition to ABCL635 and ABCL575, it is advancing a pipeline of more than 20 internal discovery programs. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Abcellera Biologics Inc is a good buy right now due to its promising clinical data and strong analyst support. The stock is currently priced at $11.8, with a forward P/E of 27.55, suggesting that while it may be overvalued in the short term, the long-term growth potential is substantial. Analysts from UBS and JPMorgan have set price targets of $18 and $17 respectively, indicating potential upside of 53% and 44%. The main risk is the negative earnings trend, with a net income loss of $43.2 million reported in Q1 2026.